-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UEYEZiZbjHnhvmsqKXFxPw+UP+wxUtKyE6U9wA4CNDqPAuHsCSqeDzW+q5dWjYSu EhR6CP8MPOePQg6AQ7dZSw== 0000893755-02-000002.txt : 20020415 0000893755-02-000002.hdr.sgml : 20020415 ACCESSION NUMBER: 0000893755-02-000002 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20011231 FILED AS OF DATE: 20020322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TECHNOLOGY FUNDING MEDICAL PARTNERS I L P CENTRAL INDEX KEY: 0000893755 IRS NUMBER: 943166762 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 814-00124 FILM NUMBER: 02583034 BUSINESS ADDRESS: STREET 1: 2000 ALAMEDA DE LAS PULGAS STE 250 CITY: SAN MATEO STATE: CA ZIP: 94403 BUSINESS PHONE: 6503452200 MAIL ADDRESS: STREET 1: 2000 ALAMEDA DE LAS PULGAS STREET 2: STE 250 CITY: SAN MATEO STATE: CA ZIP: 94403 10-K 1 mp1.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2001 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A --- --- Commission File No. 814-124 TECHNOLOGY FUNDING MEDICAL PARTNERS I, L.P. ------------------------------------------- (Exact name of Registrant as specified in its charter) DELAWARE 94-3166762 - ------------------------------- ------------------------------ (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1035 Suncast Lane, Suite 122 El Dorado Hills, California 95762 - --------------------------------------- -------- (Address of principal executive offices) (Zip Code) (916) 941-7550 -------------------------------------------------- (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Limited Partnership Units Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ] No active market for the Units of limited partnership interests (Units) exists, and therefore the market value of such Units cannot be determined. Documents incorporated by reference: Portions of the Registrant's Proxy Statement relating to the Registrant's Meeting of Limited Partners held on December 8, 2000 are incorporated by reference into Part III of this Form 10-K where indicated. PART I Item 1. BUSINESS - ------ -------- Technology Funding Medical Partners I, L.P. (the Partnership or the Registrant) is a limited partnership organized under the laws of the State of Delaware on September 3, 1992. For the period from September 3, 1992, through May 3, 1993, the Partnership was inactive. The Partnership's registration statement was declared effective by the Securities and Exchange Commission on May 3, 1993, and the Partnership began selling Units of limited partnership interest (Units) in May 1993. On October 8, 1993, the minimum number of Units required to commence Partnership operations (12,000) had been sold. The offering terminated with 79,716 Units sold on May 3, 1995. The Partnership's original contributed capital was $7,937,676, consisting of $7,929,744 from Limited Partners for 79,716 Units and $7,932 from the General Partners, Technology Funding Ltd. (TFL) and Technology Funding Inc. (TFI). The General Partners do not own any Units. The principal investment objectives of the Partnership are long- term capital appreciation from venture capital investments in new and developing companies and preservation of Limited Partner capital through risk management and active involvement with such companies (portfolio companies). The Partnership's investments in portfolio companies primarily consist of equity securities such as common and preferred shares, but also include debt convertible into equity securities and warrants and options to acquire equity securities. Although venture capital investments offer the opportunity for significant gains, such investments involve a high degree of business and financial risk that can result in substantial losses. Among these are the risks associated with investment in companies in an early stage of development or with little or no operating history, companies operating at a loss or with substantial variations in operating results from period to period, and companies with the need for substantial additional capital to support expansion or to achieve or maintain a competitive position. Such companies may face intense competition, including competition from companies with greater financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified managerial and technical personnel. There is no ready market for many of the Partnership's investments. The Partnership's investments in portfolio companies are generally subject to restrictions on sale because they were acquired from the issuer in private placement transactions or because the Partnership is an affiliate of the issuer. The Partnership has elected to be a business development company under the Investment Company Act of 1940, as amended (the Act), and operates as a non-diversified investment company, as defined in the Act. The Partnership Agreement provides that the Partnership will terminate December 31, 2002, subject to the right of the Individual General Partners to extend the term for up to two additional two-year periods. Item 2. PROPERTIES - ------ ---------- The Registrant has no material physical properties. Item 3. LEGAL PROCEEDINGS - ------ ----------------- There are no material pending legal proceedings to which the Registrant is party or of which any of its property is the subject, other than routine litigation incidental to the business of the Partnership. Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - ------ --------------------------------------------------- There were no matters submitted to a vote of the limited partners during 2001. PART II Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED - ------ ------------------------------------------------- STOCKHOLDER MATTERS ------------------- (a) There is no established public trading market for the Units. (b) At December 31, 2001, there were 841 record holders of Units. (c) The Registrant, being a partnership, does not pay dividends. Distributions of cash and securities, however, may be made to the partners in the Partnership pursuant to the Registrant's Partnership Agreement. Item 6. SELECTED FINANCIAL DATA - ------ -----------------------
For the Years Ended and As of December 31, ------------------------------------------------------- 2001 2000 1999 1998 1997 ------ ------ ------ ------ ------ Interest income $ 3,538 $ 114 $ 3 $ 693 $ 73,349 Dividend income 198 8,093 15,953 15,967 136 Net investment loss (598,897) (690,329) (539,268) (599,338) (480,820) Net realized gain (loss) from sales of equity investments 2,642,536 17,364 94,817 (331,660) 1,168 Realized losses from impairment write-downs (162,925) (300,000) -- (299,280) -- Recoveries from investments previously written off 87,223 -- -- -- -- Net (decrease) increase in unrealized appreciation of equity investments (794,482) (1,818,021) 716,138 (7,477) 1,101,284 Net increase (decrease) in partners' capital resulting from operations 1,173,455 (2,790,986) 271,687 (1,237,755) 621,632 Net increase (decrease) in partners' capital resulting from operations per Unit (1) 14.26 (34.66) 3.30 (15.37) (7.66) Total assets 4,046,194 3,514,513 5,693,057 5,672,957 6,646,391 (1) See Notes 1 and 4 to the Financial Statements for a description of the method of calculation of net increase (decrease) in partners' capital resulting from operations per Unit.
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL - ------ ------------------------------------------------- CONDITION AND RESULTS OF OPERATIONS - ----------------------------------- Liquidity and Capital Resources - ------------------------------- The Partnership operates as a business development company under the Investment Company Act of 1940 and makes venture capital investments in new and developing companies. The Partnership's financial condition is dependent upon the success of the portfolio companies. There is no ready market for many of the Partnership's investments. It is possible that some of its venture capital investments may be a complete loss or may be unprofitable and that others will appear likely to become successful, but may never realize their potential. The valuation of the Partnership's investments in securities for which there are no available market quotes is subject to the estimate of the Managing General Partners in accordance with the valuation guidance described in Note 1 to the financial statements. In the absence of readily obtainable market values, the estimated fair value of the Partnership's investments may differ significantly from the values that would have been used had a ready market existed. The Partnership Agreement provides that the Partnership will terminate December 31, 2002, unless extended for two additional two-year periods by the Individual General Partners. In September 2001, the Individual General Partners directed the Managing General Partners to proceed with the earliest reasonable termination of the Partnership after assessing the potential return on the Partnership's investments in relation to the costs of continued operation. The Managing General Partners are currently exploring alternatives for termination of the Partnership and the liquidation of its investments. During the year ended December 31, 2001, net cash used by operating activities totaled $1,243,100. The Partnership paid management fees of $255,077 to the Managing General Partners and reimbursed related parties for operating expenses of $761,784. In addition, $38,096 was paid to the Individual General Partners as compensation for their services. The Partnership paid other operating expenses of $157,133 and interest on borrowings of $32,159 and received $1,149 in interest and dividend income. During the year ended December 31, 2001, proceeds from sales of equity investments totaled $3,497,732 and recoveries from investments previously written off provided cash of $87,223. Cash and cash equivalents at December 31, 2001 were $2,378,800. Cash reserves, and future proceeds from investment sales are expected to be adequate to fund Partnership operations through the next twelve months. Results of Operations - --------------------- 2001 compared to 2000 - --------------------- The net increase in partners' capital resulting from operations was $1,173,455 for the year ended December 31, 2001, as compared to a net decrease in partners' capital resulting from operations of $2,790,986 for the year ended December 31, 2000. The change was primarily due to an increase in net gains from sales of equity investments, a decrease in unrealized depreciation on equity investments, a decrease in realized losses from impairment write- downs on investments, decreased operating expenses and an increase in recoveries from investments previously written off. Net realized gains from sales of equity investments totaled $2,642,536 and $17,364 for the years ended December 31, 2001 and 2000, respectively. The 2001 gain is attributable to the sale of the Partnership's entire investments in Endocare, Inc., CareCentric Solutions, Inc. and other smaller holdings in accordance with the directive of the Individual General Partners in September 2001 to proceed with the earliest reasonable termination of the Partnership. Unrealized depreciation on equity investments was $433,074 at December 31, 2001 and unrealized appreciation on equity investments was $361,408 at December 31, 2000. During the year ended December 31, 2001, the Partnership recorded a decrease in net unrealized appreciation on equity investments of $794,482 compared to a decrease of $1,818,021 during 2000. The 2001 decrease was primarily due to the sale of the Partnership's entire investment in Endocare, Inc. and unfavorable events and market conditions for a portfolio company in the biotechnology industry. The 2000 decrease was primarily attributable to decreases in the value of the Partnership's marketable equity securities and the fair value of the Partnership's investments in restricted securities. During the years ended December 31, 2001 and 2000, the Partnership recorded realized losses from impairment write-downs of $162,925 and $300,000, respectively. The loss in 2001 represents the Partnership's total investment in Adesso Healthcare Technology, Inc. Adesso ceased operations in the third quarter of 2001. The loss in 2000 represents the Partnership's total investment in Biex, Inc. Biex, Inc. suspended operations in November 2000 after it was unable to obtain additional funding. Investment expenses were $602,633 and $698,536 for the years ended December 31, 2001 and 2000, respectively. In 2000, the Managing General Partners billed the Partnership $158,179 for operating expenses relating to prior years that had not been fully recovered as permitted by the Partnership Agreement. If these expenses had been billed in prior years, investment expenses for 2000 would have been $540,357. The increase is primarily due to increased interest expense and increased administrative and investor services. Given the inherent risk associated with the business of the Partnership, the future performance of the portfolio company investments may significantly impact future operations. 2000 compared to 1999 - --------------------- The net decrease in partners' capital resulting from operations was $2,790,986 for the year ended December 31, 2000, compared to a net increase in partners' capital resulting from operations of $271,687 for the year ended December 31, 1999. The change was primarily due to a decrease in unrealized appreciation on equity investments, an increase in realized losses from impairment write- downs on investments, increased operating expenses and a decrease in net gains from sales of equity investments. Unrealized appreciation on equity investments was $361,408 and $2,179,429 at December 31, 2000 and 1999, respectively. During the year ended December 31, 2000, the Partnership recorded a decrease in net unrealized appreciation on equity investments of $1,818,021 compared to an increase of $716,138 during 1999. The 2000 decrease was primarily due to decreases in the value of the Partnership's marketable equity securities and the fair value of the Partnership's investments in restricted securities. During the year ended 2000, the Partnership recorded realized losses from impairment write-downs on investments of $300,000, which represents the Partnership's total investment in Biex, Inc. Biex, Inc. suspended operations in November 2000 after it was unable to obtain additional funding. There were no impairment write-downs in 1999. Investment expenses were $698,536 and $555,224 for the years ended December 31, 2000 and 1999, respectively. At a meeting on December 8, 2000, the Limited Partners approved an amendment to the Partnership Agreement which removed the limit on reimbursement of operational costs effective January 1, 2000. If the amendment had not been approved, expenses in excess of the limitation would have been $163,344 in 2000. In 2000, the Managing General Partners billed the Partnership an additional $158,179 for operating expenses relating to prior years that had not been fully recovered as permitted by the Partnership Agreement. If these expenses had been billed in prior years, investment expenses for 2000 and 1999 would have been $540,357 and $598,001, respectively. On December 8, 2000, the Limited Partners of the Partnership approved an amendment to the Partnership Agreement so that the salary and benefits of a controlling person of a Managing General Partner directly involved in carrying out the business of the Partnership are expenses of the Partnership. This resulted in additional operating expenses in 2000 of $6,193. Net realized gains from sales of equity investments totaled $17,364 and $94,817 for the years ended December 31, 2000 and 1999, respectively. The 1999 gain was primarily attributable to the sale of Valentis, Inc., partially offset by losses on the sales of Naiad Technologies, Inc. and CareCentric Solutions, Inc. Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK - ------- --------------------------------------------------------- The Partnership is subject to financial market risks, including changes in interest rates with respect to its investments in debt securities and interest bearing cash equivalents as well as changes in marketable equity security prices. The Partnership does not use derivative financial instruments to mitigate any of these risks. The return on the Partnership's investments is generally not affected by foreign currency fluctuations. The Partnership does not have a significant exposure to modest public market price fluctuations as the Partnership primarily invests in private business enterprises. However, should significant changes in market equity prices occur, there could be a longer-term effect on valuations of private companies, which could affect the carrying value and the amount and timing of gains realized on these investments. Since there is typically no public market for the Partnership's investments in private companies, the valuation of the investments is subject to the estimate of the Partnership's Managing General Partners. In the absence of a readily ascertainable market value, the estimated value of the Partnership's investments in private companies may differ significantly from the values that would be placed on the portfolio if a ready market existed. The Partnership's portfolio also includes common stocks in publicly traded companies. These investments are directly exposed to equity price risk, in that a hypothetical ten percent change in these equity prices would result in a similar percentage change in the fair value of these securities. The Partnership 's investments also include some debt securities. Since the debt securities are generally priced at a fixed rate, changes in interest rates do not directly impact interest income. The Partnership 's debt securities are generally held to maturity or converted into equity securities of private companies. Item 8. FINANCIAL STATEMENTS - ------ -------------------- The financial statements of the Registrant are set forth in Item 14. Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING - ------ ----------------------------------------------------------- AND FINANCIAL DISCLOSURE ------------------------ None PART III Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT - ------- -------------------------------------------------- As a partnership, the Registrant has no directors or executive officers. The Individual General Partners are responsible for the management and administration of the Partnership. The Individual General Partners consist of three Independent General Partners and a representative from each of Technology Funding Ltd., a California limited partnership (TFL), and its wholly owned subsidiary, Technology Funding Inc., a California corporation (TFI). TFL and TFI are the Managing General Partners. Reference is made to the information regarding Individual General Partners and the Managing General Partners in the Registrant's Proxy Statement related to the Meeting of Limited Partners held on December 8, 2000, which information is incorporated herein by reference. Item 11. EXECUTIVE COMPENSATION - ------- ---------------------- As a partnership, the Registrant has no officers or directors. In 2001, the Partnership incurred $148,024 in management fees. The fees are designed to compensate the Managing General Partners for general partner overhead incurred in performing management duties for the Partnership. General partner overhead (as defined in the Partnership Agreement) includes the General Partners' share of rent, utilities, property taxes and the cost of capital equipment and the general and administrative expenses paid by the Managing General Partners in performing their obligations to the Partnership. As compensation for their services, the Individual General Partners each receive $6,000 annually, plus $1,000 and related expenses for each attended meeting of the Individual General Partners or committees thereof. For the year ended December 31, 2001, $38,096 of such fees were paid. Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND - ------- --------------------------------------------------- MANAGEMENT - ---------- Not applicable. No Limited Partner beneficially holds more than 5 percent of the aggregate number of Units held by all Limited Partners, and neither the General Partners nor any of their officers, directors or partners own any Units. The three Individual General Partners each own 20 Units. The Individual General Partners control the affairs of the Partnership pursuant to the Partnership Agreement. Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS - ------- ---------------------------------------------- The Registrant, or its investee companies, have engaged in no transactions with the General Partners or their officers and partners other than as described above, in the notes to the financial statements, or in the Partnership Agreement. PART IV Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON - ------- ------------------------------------------------------ FORM 8-K -------- (a) List of Documents filed as part of this Annual Report on Form 10-K (1) Financial Statements - the following financial statements are filed as a part of this Report: Report of Independent Public Accountants as of and for the years ended December 31, 2001 and 2000 Independent Auditors' Report for the year ended December 31, 1999 Balance Sheets as of December 31, 2001 and 2000 Statements of Investments as of December 31, 2001 and 2000 Statements of Operations for the years ended December 31, 2001, 2000 and 1999 Statements of Partners' Capital for the years ended December 31, 2001, 2000 and 1999 Statements of Cash Flows for the years ended December 31, 2001, 2000 and 1999 Notes to Financial Statements (2) Financial Statement Schedules All schedules have been omitted because they are not applicable or the required information is included in the financial statements or the notes thereto. (3) Exhibits None (b) Reports on Form 8-K No reports on Form 8-K were filed by the Registrant during the year ended December 31, 2001. REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS - ---------------------------------------- To the Partners of Technology Funding Medical Partners I, L.P.: We have audited the accompanying balance sheets of Technology Funding Medical Partners I, L.P. (a Delaware limited partnership) (the Fund), including the statements of investments, as of December 31, 2001 and 2000, and the related statements of operations, partners' capital, and cash flows for the years then ended. These financial statements are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our procedures included physical inspection of securities owned as of December 31, 2001 and 2000. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Technology Funding Medical Partners I, L.P. as of December 31, 2001 and 2000, and the results of its operations, changes in partners' capital, and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States. Los Angeles, California /S/ARTHUR ANDERSEN LLP March 15, 2002 INDEPENDENT AUDITORS' REPORT ---------------------------- The Partners Technology Funding Medical Partners I, L.P.: We have audited the accompanying statements of operations, partners' capital, and cash flows of Technology Funding Medical Partners I, L.P. (a Delaware limited partnership) for the year ended December 31, 1999. These financial statements are the responsibility of the Partnership's management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the results of operations and cash flows of Technology Funding Medical Partners I, L.P. for the year ended December 31, 1999, in conformity with accounting principles generally accepted in the United States of America. Albuquerque, New Mexico /S/KPMG LLP March 29, 2000 BALANCE SHEETS - --------------
December 31, ------------------- 2001 2000 ------ ------ ASSETS Equity investments (cost basis of $2,099,412 and $3,114,946 in 2001 and 2000, respectively) $1,666,338 $3,476,354 Cash and cash equivalents 2,378,800 36,945 Other assets 1,056 1,214 --------- --------- Total assets $4,046,194 $3,514,513 ========= ========= LIABILITIES AND PARTNERS' CAPITAL Accounts payable and accrued expenses $ 40,801 $ 46,855 Due to related parties 3,772 639,492 --------- --------- Total liabilities 44,573 686,347 Commitments and contingencies Partners' capital (79,716 Limited Partner Units outstanding) 4,001,621 2,828,166 --------- --------- Total liabilities and partners' capital $4,046,194 $3,514,513 ========= =========
The accompanying notes are an integral part of these financial statements STATEMENTS OF INVESTMENTS - -------------------------
Principal amount or December 31, 2001 December 31, 2000 Industry shares at ----------------- ----------------- (1) Investment December 31, Cost Fair Cost Fair Company Position Date 2001 Basis Value Basis Value - ------------- -------- ------ ------------ ----- ----- ----- ----- Equity Investments - ------------------ Medical/Biotechnology - --------------------- 26.8% and 57.4% at December 31, 2001 and 2000, respectively - ----------------------------------------------------------- Acusphere, Inc. Preferred 1995- (a) shares 1997 340,635 $ 706,251 $ 970,810 $ 706,251 $ 970,810 Curis, Inc. Common shares 2000 -- -- -- 27,033 20,528 Prolinx, Inc. Preferred (a) (b) shares 2001 30,417 27,355 13,688 688,461 621,924 Prolinx, Inc. Common 1995- (a) (b) shares 1998 197,436 688,461 88,846 -- -- Prolinx, Inc. Convertible (a) (b) note 2000 -- -- -- 26,809 9,383 Prolinx, Inc. Preferred (a) (b) share warrants at $.90; expiring 2010) 2001 7,416 293 0 -- -- --------- --------- --------- --------- 1,422,360 1,073,344 1,448,554 1,622,645 --------- --------- --------- --------- STATEMENTS OF INVESTMENTS (continued) - ------------------------------------ Medical/Diagnostic Equipment - ---------------------------- 10.7% and 51.4% at December 31, 2001 and 2000, respectively - ----------------------------------------------------------- Endocare, Inc. Common 1996- shares 2000 -- -- -- 556,000 1,162,800 LifeCell Preferred 1996- Corporation shares (2) 2001 2,867 247,500 229,967 247,500 141,137 LifeCell Common Corporation share warrant at $4.13; expired 2001 1996 -- -- -- 2,500 0 R2 Technology, Preferred 1994- Inc. (a) shares 1996 117,134 134,268 197,820 134,268 148,364 --------- --------- --------- --------- 381,768 427,787 940,268 1,452,301 --------- --------- --------- --------- Health Information Systems - -------------------------- 0.0% and 1.4% at December 31, 2001 and 2000, respectively - --------------------------------------------------------- Adesso Healthcare Technology Services, Inc. Preferred 1997- (a) (b) shares 2000 -- -- -- 131,048 0 Adesso Healthcare Technology Services, Inc. Convertible (a) (b) note 2000 -- -- -- 30,128 22,596 STATEMENTS OF INVESTMENTS (continued) - ------------------------------------ CareCentric Common Solutions, Inc. shares 1999 -- -- -- 94,899 15,898 --------- --------- --------- --------- -- -- 256,075 38,494 --------- --------- --------- --------- Pharmaceuticals - --------------- 0.0% and 3.2% at December 31, 2001 and 2000, respectively - --------------------------------------------------------- Axys Pharmaceuticals, Common Inc. shares 2000 -- -- -- 47,000 56,250 Periodontix, Preferred 1993- Inc. (a) shares 1996 167,000 234,000 0 234,000 35,100 --------- --------- --------- --------- 234,000 0 281,000 91,350 --------- --------- --------- --------- Environmental - ------------- 0.0% and 0.1% at December 31, 2001 and 2000, respectively - --------------------------------------------------------- Triangle Biomedical Sciences, Common Inc. (a) shares 1999 366 10,248 1,025 10,248 3,587 Triangle Common Biomedical share Sciences, warrant Inc. (a) at $28.00; expiring 2009 1999 366 366 37 366 128 --------- --------- --------- --------- 10,614 1,062 10,614 3,715 --------- --------- --------- --------- STATEMENTS OF INVESTMENTS (continued) - ------------------------------------ Venture Capital Limited Partnership Investments - ----------------------------------------------- 4.1% and 9.5% at December 31, 2001 and 2000, respectively - --------------------------------------------------------- Medical Science Limited Partners II, L.P. Partnership (a) Interests various $250,000 50,670 164,145 178,435 267,849 --------- --------- --------- --------- 50,670 164,145 178,435 267,849 --------- --------- --------- --------- Total equity investments-41.6% and 123.0% at December 31, 2001 and 2000, respectively $2,099,412 $1,666,338 $3,114,946 $3,476,354 ========= ========= ========= ========= Legend and footnotes: -- No investment held at end of period. 0 Investment active with a carrying value or fair value of zero. (a) Equity security acquired in a private placement transaction; resale may be subject to certain selling restrictions. (b) Portfolio company is an affiliate of the Partnership; resale may be subject to certain selling restrictions. (1) Represents the total fair value of a particular industry segment as a percentage of partners' capital at December 31, 2001 and 2000. (2) The Partnership has no income-producing equity investments except for LifeCell Corporation Preferred shares.
The accompanying notes are an integral part of these financial statements. STATEMENTS OF OPERATIONS - ------------------------
For the Years Ended December 31, ------------------------------------ 2001 2000 1999 ------ ------ ------ Investment income: Interest income $ 3,538 $ 114 $ 3 Dividend income 198 8,093 15,953 --------- --------- ------- Total investment income 3,736 8,207 15,956 Investment expenses: Management fees 148,024 158,597 158,597 Individual General Partners' compensation 38,096 35,817 38,323 Administrative and investor services 208,476 171,568 223,119 Investment operations 34,583 199,446 28,756 Computer services 54,461 39,158 40,720 Professional fees 86,834 89,712 43,071 Interest expense 32,159 4,238 22,638 --------- --------- ------- Total investment expenses 602,633 698,536 555,224 --------- --------- ------- Net investment loss (598,897) (690,329) (539,268) --------- --------- ------- Net realized gain from sale of equity investments 2,642,536 17,364 94,817 Realized losses from impairment write-downs (162,925) (300,000) -- Recoveries from investments previously written off 87,223 -- -- --------- --------- ------- Net realized income (loss) 2,566,834 (282,636) 94,817 --------- --------- ------- Net (decrease) increase in unrealized appreciation of equity investments (794,482) (1,818,021) 716,138 --------- --------- ------- Net increase (decrease) in partners' capital resulting from operations $1,173,455 $(2,790,986) $271,687 ========= ========= ======= Net increase (decrease) in partners' capital resulting from operations per Unit $ 14.26 $ (34.66) $ 3.30 ========= ========= =======
The accompanying notes are an integral part of these financial statements. STATEMENTS OF PARTNERS' CAPITAL - -------------------------------
For the years ended December 31, 2001, 2000 and 1999: Limited General Partners Partners Total -------- -------- ----- Partners' capital, January 1, 1999 $5,353,676 $(6,211) $5,347,465 Net investment loss (520,302) (18,966) (539,268) Net realized income 91,482 3,335 94,817 Net increase in unrealized appreciation 691,641 24,497 716,138 --------- ------ --------- Partners' capital, December 31, 1999 5,616,497 2,655 5,619,152 Net investment loss (683,425) (6,904) (690,329) Net realized loss (279,810) (2,826) (282,636) Net decrease in unrealized appreciation (1,799,841) (18,180) (1,818,021) --------- ------ --------- Partners' capital, December 31, 2000 2,853,421 (25,255) 2,828,166 Net investment loss (579,880) (19,017) (598,897) Net realized income 2,485,330 81,504 2,566,834 Net decrease in unrealized appreciation (768,732) (25,750) (794,482) --------- ------ --------- Partners' capital, December 31, 2001 $3,990,139 $11,482 $4,001,621 ========= ====== =========
The accompanying notes are an integral part of these financial statements. STATEMENTS OF CASH FLOWS - ------------------------
For the Years Ended December 31, ----------------------------------- 2001 2000 1999 ------ ------ ------ Net increase (decrease) in partners' capital resulting from operations $1,173,455 $(2,790,986) $ 271,687 Adjustments to reconcile net increase (decrease) in partners' capital resulting from operations to net cash used by operating activities: Net decrease (increase) in unrealized appreciation of equity investments 794,482 1,818,021 (716,138) Net realized gain from sales of equity investments (2,642,536) (17,364) (94,817) Realized losses from impairment write-downs 162,925 300,000 -- Recoveries from investments previously written off (87,223) -- -- (Decrease) increase in accounts payable and accrued expenses (6,054) 11,328 (3,371) (Decrease) increase in due to related parties (635,720) 603,761 (48,426) Other changes, net (2,429) (280) (123) --------- --------- ------- Net cash used by operating activities (1,243,100) (75,520) (591,188) --------- --------- ------- Cash flows from investing activities: Proceeds from sales of equity investments 3,497,732 143,131 966,581 Purchases of equity investments -- (224,874) -- Recoveries from investments previously written off 87,223 -- -- Distribution from venture capital limited partnership investment -- 20,864 -- --------- --------- ------- Net cash provided (used) by investing activities 3,584,955 (60,879) 966,581 --------- --------- ------- STATEMENTS OF CASH FLOWS (continued) - ----------------------------------- For the Years Ended December 31, ----------------------------------- 2001 2000 1999 ------ ------ ------ Cash flows from financing activities: Repayment of short-term borrowings -- (2,646) (199,790) --------- --------- ------- Net cash used by financing activities -- (2,646) (199,790) --------- --------- ------- Net increase (decrease) in cash and cash equivalents 2,341,855 (139,045) 175,603 Cash and cash equivalents at beginning of year 36,945 175,990 387 --------- --------- ------- Cash and cash equivalents at end of year $2,378,800 $ 36,945 $ 175,990 ========= ========= =======
The accompanying notes are an integral part of these financial statements. NOTES TO FINANCIAL STATEMENTS - ----------------------------- 1. Summary of Significant Accounting Policies ------------------------------------------ Organization - ------------ Technology Funding Medical Partners I, L.P. (the Partnership or the Registrant) is a limited partnership organized under the laws of the State of Delaware on September 3, 1992. The purpose of the Partnership is to make venture capital investments in emerging growth companies. The Partnership elected to be treated as a business development company under the Investment Company Act of 1940, as amended (the Act), and operates as a non-diversified investment company, as defined in the Act. The Managing General Partners are Technology Funding Ltd. (TFL), and Technology Funding Inc. (TFI), a wholly owned subsidiary of TFL. There are also three Individual General Partners. For the period from September 3, 1992, through May 3, 1993, the Partnership was inactive. The Partnership's registration statement was declared effective by the Securities and Exchange Commission on May 3, 1993, and the Partnership began selling Units of limited partnership interest (Units) in May 1993. On October 8, 1993, the minimum number of Units required to commence Partnership operations (12,000) had been sold. The offering terminated with 79,716 Units sold on May 3, 1995. The Partnership's original contributed capital was $7,937,676, consisting of $7,929,744 from Limited Partners for 79,716 Units and $7,932 from General Partners. The General Partners do not own any Units. The Partnership Agreement provides that the Partnership will continue until December 31, 2002, unless further extended for up to two additional two-year periods from such date if the Individual General Partners so determine or unless sooner dissolved. In September 2001, the Individual General Partners directed the Managing General Partners to proceed with the earliest reasonable termination of the Partnership after assessing the potential return on the Partnership's investments in relation to the costs of continued operation. The Managing General Partners are currently exploring alternatives for termination of the Partnership and the liquidation of its investments. Preparation of Financial Statements and Use of Estimates - -------------------------------------------------------- The accompanying financial statements have been prepared on the accrual basis of accounting. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the estimate of fair value of investments, liabilities and contingencies. Because of the inherent uncertainty of valuation, the estimated fair value of investments may differ significantly from the values that would have been used had a ready market for investments existed, and the differences could be material. Equity Investments - ------------------ Investments are carried at fair value. Under the direction and control of the Individual General Partners, the Managing General Partners are delegated the authority to establish valuation procedures and periodically apply such procedures to the Partnership's investment portfolio. In fulfilling this responsibility, the Managing General Partners periodically update and revise the valuation procedures used to determine fair value in order to reflect new events, changing market conditions, more experience with investee companies or additional information, any of which may require the revision of previous estimating procedures. Unrestricted publicly traded securities are valued at the closing sales price or bid price that is available on a national securities exchange or over-the-counter market. Valuation discounts of 5 percent to 50 percent are applied to publicly traded securities subject to resale restrictions resulting from Rule 144 or contractual lock-ups, such as those commonly associated with underwriting agreements or knowledge of material non-public information. The fair value of all other investments is determined in good faith by the Managing General Partners under the delegated authority of the Individual General Partners after consideration of available relevant information. There is no ready market for the Partnership's investments in private companies or unregistered securities of public companies. Fair value is generally defined as the amount the Partnership could reasonably expect to receive for an investment in an orderly disposition based on a current sale. Significant factors considered in the estimation of fair value include the inherent illiquidity of and lack of marketability associated with venture capital investments in private companies or unregistered securities, the investee company's enterprise value established in the last round of venture financing, changes in market conditions since the last round of venture financing or since the last reporting period, the value of a minority interest in the investee company, contractual restrictions on resale typical of venture financing instruments, the investee company's financial position and ability to obtain any necessary additional financing, the investee company's performance as compared to its business plan, and the investee company's progress towards initial public offering. The values determined for the Partnership's investments in these securities are based upon available information at the time the good faith valuations are made and do not necessarily represent the amount which might ultimately be realized, which could be higher or lower than the reported fair value. At December 31, 2001 and 2000, the investment portfolio included investments totaling $1,272,222 and $1,811,892, respectively, whose fair values were established in good faith by the Managing General in the absence of readily ascertainable market values. In addition, investments in publicly traded securities which have been subjected to a discount for legal or contractual restrictions as determined by the Managing General Partners amounted to $0 and $1,163,312 at December 31, 2001 and 2000, respectively. Because of the inherent uncertainty in the valuation, the values may differ significantly from the values that would have been used had a ready market for the securities existed, and the differences could be material. Venture capital limited partnership investments are valued based on the fair value of the underlying investments. Limited partnership distributions that are a return of capital reduce the cost basis of the Partnership's investment. Distributions from limited partnership cumulative earnings are reflected as realized gains by the Partnership. In the case of an other-than-temporary decline in value below cost basis, an appropriate reduction in the cost basis is recognized as a realized loss with the new cost basis being adjusted to equal the fair value of the investment. Cost basis adjustments are reflected as "Realized losses from impairment write-downs" on the Statements of Operations. Sales of equity investments are recorded on the trade date. The basis on which cost is determined in computing realized gains or losses is specific identification. Cash and Cash Equivalents - ------------------------- Cash and cash equivalents are principally comprised of cash invested in demand accounts and money market instruments and are stated at cost plus accrued interest. The Partnership considers all money market and short- term investments with an original maturity of three months or less to be cash equivalents. Net Increase (Decrease) in Partners' Capital Resulting from Operations - ---------------------------------------------------------------------- Per Unit - -------- Net increase (decrease) in partners' capital resulting from operations per Unit is calculated by dividing the weighted average number of Units outstanding of 79,716 for the years ended December 31, 2001, 2000 and 1999, into the total net increase (decrease) in partners' capital resulting from operations allocated to the Limited Partners. The Managing General Partners contributed 0.1 percent of total Limited Partner capital contributions and did not receive any Partnership Units. Provision for Income Taxes - -------------------------- No provision for income taxes has been made by the Partnership as the Partnership is not directly subject to taxation. The partners are to report their respective shares of Partnership income or loss on their individual tax returns. The accompanying financial statements are prepared using accounting principles generally accepted in the United States which may not equate to tax accounting. The cost of investments on a tax basis at December 31, 2001 and 2000, was $2,290,848 and $3,187,729, respectively. At December 31, 2001 and 2000, gross unrealized depreciation and appreciation on investments based on cost for federal income tax purposes were as follows:
December 31, December 31, 2001 2000 ------------ ------------ Unrealized appreciation $ 386,084 $1,068,550 Unrealized depreciation (1,010,594) (779,925) --------- --------- Net unrealized (depreciation) appreciation $ (624,510) $ 288,625 ========= =========
2. Financing of Partnership Operations ----------------------------------- The Managing General Partners expect cash received from the future liquidation of Partnership investments and short-term borrowings will provide the necessary liquidity to fund Partnership operations. The Partnership may be dependent upon the financial support of the Managing General Partners to fund operations if future proceeds are not received timely. The Managing General Partners have committed to support the Partnership's working capital requirements through short-term advances as necessary. 3. Related Party Transactions -------------------------- Included in costs and expenses are related party costs as follows:
For the Years Ended December 31, ------------------------------- 2001 2000 1999 ------ ------ ------ Management fees $148,024 $158,597 $158,597 Individual General Partners' compensation 38,096 35,817 38,323 Reimbursable operating expenses: Administrative and investor services 150,075 98,363 140,015 Investment operations 28,581 193,778 24,050 Computer services 54,461 39,158 40,720
Management fees are equal to 2 percent of the total Limited Partner capital contributions for the first year of Partnership operations through the sixth year. Beginning in the seventh year (May 2001), management fees declined by 10 percent per year from the initial 2 percent. Management fees compensate the Managing General Partners solely for general partner overhead (as defined in the Partnership Agreement) incurred in supervising the operation and management of the Partnership and the Partnership's investments. Management fees due to the Managing General Partners were $11,895 and $118,948 and were included in due to related parties at December 31, 2001 and 2000, respectively. The Partnership reimburses the Managing General Partners for certain operating expenses incurred in connection with the business of the Partnership. Reimbursable operating expenses paid by the Managing General Partners include expenses (other than organizational and offering expenses and general partner overhead) such as administrative and investor services, investment operations, and computer services. Prior to 2000, the Partnership Agreement stated that the Partnership could not reimburse the Managing General Partners for certain operational costs that aggregate more than 3 percent of total Limited Partner capital contributions. On December 8, 2000, the Limited Partners approved an amendment to the Partnership Agreement which removed the limit on reimbursement of operational costs effective January 1, 2000. Amounts due from related parties were $8,123 at December 31, 2001 and amounts due to related parties were $520,544 at December 31, 2000. The Managing General Partners allocate operating expenses incurred in connection with the business of the Partnership based on employee hours incurred. In 2000, the Managing General Partners billed the Partnership an additional $158,179 for investment management expenses consisting of $42,777 and $115,402 for 1999 and prior years, respectively, that were incurred by the General Partners but not previously billed to the Partnership. Had the additional expenses been billed in prior years, investment expenses would have been $540,357 and $598,001 for 2000 and 1999, respectively. As compensation for their services, the Individual General Partners each receive $6,000 annually beginning on the Commencement Date, plus $1,000 and related expenses for each attended meeting of the Individual General Partners or committee thereof. The three Individual General Partners each own twenty Units. Under the terms of a computer service agreement, Technology Administrative Management, a division of TFL, charges the Partnership for its share of computer support costs. These amounts are included in computer services expenses. Officers of the Managing General Partners occasionally receive stock options as compensation for serving on the Boards of Directors of portfolio companies. It is the Managing General Partners' policy that all such compensation be transferred to the investing partnerships. If the options are non-transferable, they are not recorded as an asset of the Partnership. Any profit from the exercise of such options will be transferred if and when the options are exercised and the underlying stock is sold by the officers. Any such profit is allocated amongst the Partnership and affiliated partnerships based on their proportionate investments in the portfolio company. At December 31, 2001, the Partnership and affiliated partnerships had an indirect interest in non-transferable Endocare, Inc. options with a fair value of $213,169. 4. Allocation of Profits and Losses -------------------------------- In accordance with the Partnership Agreement (see Note 1), net profits and losses of the Partnership are allocated based on the beginning-of-the-year partners' capital balances as follows: (a) Profits: (i) first, to those partners with deficit capital account balances in proportion to such deficits until the deficits have been eliminated; then (ii) second, to the partners as necessary to offset net decrease in partners' capital resulting from operations and sales commissions previously allocated to such partners; then (iii) third, 75 percent to the Limited Partners as a group in proportion to the number of Units, 5 percent to the Limited Partners in proportion to the Unit months of each Limited Partner, and 20 percent to the Managing General Partners. Unit months are the number of half months a Unit would be outstanding if held from the date the original holder of such Unit was deemed admitted into the Partnership until the termination of the offering of Units. (b) Losses: (i) first, to the partners as necessary to offset net profit previously allocated to the partners under (a)(iii) above plus losses from unaffiliated venture capital limited partnership investments; then (ii) 99 percent to the Limited Partners as a group and 1 percent to the Managing General Partners. Losses allocable to Limited Partners in excess of their capital account balances will be allocated to the Managing General Partners. Net profit thereafter, otherwise allocable to those Limited Partners, would be allocated to the Managing General Partners to the extent of such losses. As indicated above, losses from unaffiliated venture capital limited partnership investments are allocated pursuant to section (b). Gains are allocated 99 percent to Limited Partners and 1 percent to the Managing General Partners. In no event shall the General Partners' interest in profits and losses be less than 1 percent. 5. Equity Investments ------------------ All investments are valued at fair value as determined in good faith by the Managing General Partners. See Note 1--Equity Investments. Marketable Equity Securities - ---------------------------- At December 31, 2001 and 2000, marketable equity securities had an aggregate cost of $247,504 and $395,208, respectively, and an aggregate fair value of $229,971 and $233,301, respectively. The unrealized loss at December 31, 2001 and 2000, included gross gains of $0 and $9,250, respectively. Restricted Securities - --------------------- At December 31, 2001 and 2000, restricted securities had aggregate fair values of $1,436,367 and $3,243,053, respectively, representing 35.9 percent and 114.7 percent, respectively, of the net assets of the Partnership. Significant purchases and sales of investments during the year ended December 31, 2001 are as follows: Adesso Healthcare Technology Services, Inc. - ------------------------------------------- The company ceased operations during the third quarter of 2001 and the Partnership is not expecting any returns on its investments. Preferred shares and convertible notes totaling $162,925 were written off as of September 30, 2001. Axys Pharmaceuticals, Inc. - -------------------------- In September 2001, the Partnership sold 10,000 common shares in the company for proceeds of $34,394 and realized a loss of $12,606. CareCentric Solutions, Inc. - --------------------------- In November 2001, the Partnership sold 11,839 common shares in the company for proceeds of $12,444 and realized a loss of $82,455. Curis, Inc. - ----------- In September 2001, the Partnership sold 2,313 common shares in the company for proceeds of $13,762 and realized a loss of $13,271. deCODE Genetics, Inc. - --------------------- In September 2001, the Partnership sold 4,887 common shares in the company for proceeds of $35,039 and realized a loss of $8,944. Endocare, Inc. - -------------- In December 2001, the Partnership sold 182,400 common shares for proceeds of $3,299,902 and realized a gain of $2,743,902. Inspire Pharmaceuticals, Inc. - ----------------------------- In September 2001, the Partnership sold 9,309 common shares in the company for proceeds of $102,191 and realized a gain of $18,410. Periodontix, Inc. - ----------------- The assets of the company have been acquired by Demegen, Inc. effective July 16, 2001; the purchase price is payable in stock over an extended period of time. Based on the December 31, 2001 closing stock price of Demegen, the current fair value of the Partnership's investment in the company is $0. Prolinx, Inc. - ------------- In May 2001, the company recapitalized and the Partnership's Preferred shares were converted into 197,436 common shares. The Partnership also converted a note, together with interest, totaling $27,355 into 30,417 Series A Preferred shares in conjunction with the recapitalization. R2 Technology, Inc. - ------------------- The company filed an S-1 Registration Statement in December 2001. Venture Capital Limited Partnership Investments - ----------------------------------------------- During 2001, the Partnership received stock distributions of deCODE Genetics, Inc. and Inspire Pharmaceuticals, Inc. with fair market values totaling $127,765. These distributions were recorded as a return of capital. In the year ended December 31, 2001, the Partnership recorded a $24,061 increase in fair value as a result of a net increase in the fair value of the underlying investments of the partnership, partially offset by decreases due to the above distributions. Other Equity Investments - ------------------------ Other significant changes reflected in the Statements of Investments relate to market value fluctuations for publicly-traded portfolio companies or changes in the fair value of private companies as determined in accordance with the policy described in Note 1 to the financial statements. 6. Net (Decrease) Increase in Unrealized Appreciation of Equity ------------------------------------------------------------ Investments ----------- In accordance with the accounting policy as stated in Note 1, the Statements of Operations include a line item entitled "Net (decrease) increase in unrealized appreciation of equity investments." The table below discloses details of the changes:
For the Years Ended December 31, ------------------------------------ 2001 2000 1999 -------- -------- -------- Unrealized (depreciation) appreciation from cost of marketable equity securities $ (17,533) $ (161,907) $1,134,112 Unrealized (depreciation) appreciation from cost of non-marketable equity securities (415,541) 523,315 1,045,317 --------- --------- --------- Unrealized (depreciation) appreciation from cost at end of year (433,074) 361,408 2,179,429 Unrealized appreciation from cost at beginning of year 361,408 2,179,429 1,463,291 --------- --------- --------- Net (decrease) increase in unrealized appreciation of equity investments $ (794,482) $(1,818,021) $ 716,138 ========= ========= =========
7. Cash and Cash Equivalents ------------------------- Cash and cash equivalents at December 31, 2001 and 2000, consisted of:
2001 2000 ------ ------ Demand accounts $ 13,501 $36,873 Money-market accounts 2,365,299 72 --------- ------ Total $2,378,800 $36,945 ========= ======
8. Short-Term Borrowings --------------------- The Partnership had a borrowing account with a financial institution which was secured by the Partnership's Endocare shares. The outstanding balance of $932,778 was repaid upon the sale of these shares in December 2001. The weighted-average interest rate for the year ended December 31, 2001 was 6.29 percent. Interest expense totaled $32,159 for the year ended December 31, 2001. 9. Commitments and Contingencies ----------------------------- The Partnership is a party to financial instruments with off-balance-sheet risk in the normal course of its business. Generally, these instruments are commitments for future equity investment fundings, equipment financing commitments, or accounts receivable lines of credit that are outstanding but not currently fully utilized by a borrowing company. As they do not represent current outstanding balances, these unfunded commitments are properly not recognized in the financial statements. At December 31, 2001, there were no unfunded investment commitments to portfolio companies and venture capital limited partnerships. The Partnership is involved in various claims and legal actions incident to its operations, which in the opinion of the Managing General Partners, based upon advice of counsel, will not materially affect the financial position or results of operations of the Partnership. 10. Financial Highlights --------------------
For The Years Ended December 31, ----------------------------------- 2001 2000 1999 ------ ------ ------ (all amounts on a per Unit basis) Net asset value, beginning of period $35.79 $70.45 $67.15 Income (loss) from investment operations: Net investment loss (7.27) (8.57) (6.52) Net realized and unrealized gain (loss) on investments 21.53 (26.09) 9.82 ------ ------ ------ Total from investment operations 14.26 (34.66) 3.30 ------ ------ ------ Net asset value, end of period $50.05 $35.79 $70.45 ====== ====== ====== Total Return 39.84% (49.20)% 4.91% Ratios to average net assets: Net investment income (loss) (16.95)% (16.14)% (9.49)% Expenses 17.61% 16.49% 10.12%
SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. TECHNOLOGY FUNDING MEDICAL PARTNERS I, L.P. By: TECHNOLOGY FUNDING INC. TECHNOLOGY FUNDING LTD. Managing General Partners Date: March 20, 2002 By: /s/Charles R. Kokesh --------------------- Charles R. Kokesh President, Chief Executive Officer, Chief Financial Officer and Chairman of Technology Funding Inc. and Managing General Partner of Technology Funding Ltd. Pursuant to the requirements of the Securities Exchange Act of 1934, this Report on Form 10-K has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: Signature Capacity Date --------- -------- ---- /s/Charles R. Kokesh President, Chief March 20, 2002 - ------------------------ Executive Officer, Charles R. Kokesh Chief Financial Officer and Chairman of Technology Funding Inc. and Managing General Partner of Technology Funding Ltd. The above represents a majority of the Board of Directors of Technology Funding Inc. and the General Partners of Technology Funding Ltd. -----END PRIVACY-ENHANCED MESSAGE-----